Clinical Social Workers in Roy, WA Accepting Medicare
3 Clinical Social Workers found. Showing 1 - 3
 Mrs. Carla Sue Chase, SOCIAL WORKER Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 40717 5th Avenue South, Roy, WA 98580 Phone: 253-968-4193 Fax: 253-968-4249 |
Kendra Dawn Cullimore, MSW, LICSWA Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 34303 27th Ave E, Roy, WA 98580 Phone: 253-326-2318 |
Sydney Nichole Smith, MSW, LSWAIC Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 36106 48th Ave S, Roy, WA 98580 Phone: 253-380-6142 |
News Archive
Cytheris broadens patent protection for recombinant human interleukin-7
Cytheris SA, a clinical stage biopharmaceutical company focused on research and development of new therapies for immune modulation, today announced that it has received a Notice of Allowance from the U.S. Patent and Trademark Office (USPTO) for its patent application "Glycosylated IL-7, Preparation and Uses", US Patent Application Number 11/996,176. The Notice of Allowance is the USPTO's official communication that the Company's application has successfully completed examination and that a patent will be issued.
Surgery improves survival in late-stage NSCLC patients
Patients with late-stage, non-small cell lung cancer (NSCLC) who have surgery have better survival rates than those who don't, but fewer of these patients are undergoing surgery, UC Davis researchers have found.
Research: Specific gene action during exposure to adolescent trauma is critical for development of PTSD
Research led by Ya-Ping Tang, MD, PhD, Associate Professor of Cell Biology and Anatomy at LSU Health Sciences Center New Orleans, has found that the action of a specific gene occurring during exposure to adolescent trauma is critical for the development of adult-onset Post-Traumatic Stress Disorder (PTSD.)
Breast cancer patients who achieve pathological complete response have better outcomes
Locally advanced breast cancer patients who received the same class of neoadjuvant chemotherapy were found to have no evidence of disease at the time of their surgery, or achieved pathological complete response, at the same rate regardless of race, according to researchers at The University of Texas M. D. Anderson Cancer Center.
Genentech, Biogen announce FDA approval of Rituxan to treat follicular lymphoma
Genentech, a member of the Roche Group, and Biogen Idec today announced the U.S. Food and Drug Administration approved Rituxan as a maintenance treatment for patients with advanced follicular lymphoma who responded to initial treatment with Rituxan plus chemotherapy.
› Verified 4 days ago